Old Revisions

These are the older revisons of the current document. To revert to an old revision, select it from below, click Edit this page and save it.

2026/02/13 00:17 endocrine:glp1:semaglutide – [Clinical Pearls] andrew2393cns +24 B (current)
2026/02/13 00:16 endocrine:glp1:semaglutide – [GLP-1 vs SGLT2 in Cardiovascular Disease] andrew2393cns +16 B
2026/02/13 00:16 endocrine:glp1:semaglutide – [Semaglutide vs Other GLP-1 Agents] andrew2393cns +36 B
2026/02/13 00:16 endocrine:glp1:semaglutide – [Contraindications] andrew2393cns +16 B
2026/02/13 00:16 endocrine:glp1:semaglutide – [Adverse Effects] andrew2393cns +28 B
2026/02/13 00:16 endocrine:glp1:semaglutide – [Dosing Forms] andrew2393cns +24 B
2026/02/13 00:15 endocrine:glp1:semaglutide – [Atherosclerotic Cardiovascular Disease (ASCVD) ★] andrew2393cns +12 B
2026/02/13 00:15 endocrine:glp1:semaglutide – [Obesity ★] andrew2393cns +12 B
2026/02/13 00:15 endocrine:glp1:semaglutide – [Mechanism of Action] andrew2393cns +32 B
2026/02/13 00:15 endocrine:glp1:semaglutide – [Semaglutide] andrew2393cns +12 B
2026/02/13 00:15 endocrine:glp1:semaglutide – created andrew2393cns +4 KB